|
|
Article: Statement by Palatin Technologies.
- Article from:
- Business Wire
- Article date:
- September 14, 1998
CopyrightCOPYRIGHT 1998 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PRINCETON, N.J.--(BW HealthWire)--Sept. 14, 1998--Palatin Technologies Inc. (Nasdaq:PLTN) Monday said that it knows of no fundamental reason for the recent decline in its stock price.
According to the announcement by Chairman, President and Chief Executive Officer Edward J. Quilty, clinical trials for LeuTech(R), the company's radiolabeled diagnostic kit for infection imaging, are proceeding on schedule, with enrollment of patients at multiple sites beginning this week for a pivotal Phase 3 trial of LeuTech for the diagnosis of difficult-to-diagnose appendicitis.
Quilty commented: "We intend to complete the appendicitis trials for LeuTech by ...